Immunovia Earnings Call: PancreaSure Builds, Risks Remain

Immunovia AB ((SE:IMMNOV)) has held its Q4 earnings call. Read on for the main highlights of the call.

Immunovia’s latest earnings call mixed optimism with caution as management highlighted a successful launch of PancreaSure alongside tight cost control and scientific momentum, but also stressed that revenues remain minimal and financing risk persists. Investors heard a story of strong strategic positioning in pancreatic cancer surveillance yet with a long, uncertain road to full reimbursement and meaningful cash inflows.

Commercial Launch of PancreaSure

PancreaSure was commercially launched in September 2025, focusing on high‑risk pancreatic surveillance centers rather than broad primary care. By year‑end, six centers were regularly using the test, with four additional centers added in the fourth quarter, and UC Health alone has already run more than 100 tests.

Early Traction at Key Centers

Management reported encouraging order activity from prominent institutions such as Northwestern Medicine and HonorHealth, signaling early clinical acceptance among opinion‑leading centers. The commercial pipeline now includes six centers in regular use, six in early adoption, eight registered and nine in late‑stage discussions.

Attractive Medicare Pricing Secured

The company has locked in a Medicare reimbursement rate of USD 897 per PancreaSure test and secured an appropriate billing code, establishing a favorable pricing benchmark. This positions Immunovia for substantial per‑test revenue potential once coverage decisions are granted and volumes scale.

Robust Scientific and Clinical Validation

Immunovia underscored strong scientific backing with five clinical studies published in peer‑reviewed journals and multiple podium presentations showcasing PancreaSure data. The CLARITI study being named best of DDW further strengthens the test’s credibility and visibility among gastroenterologists and oncologists.

Regulatory Progress Across U.S. States

The company’s laboratory and service approvals now span 48 of 50 U.S. states, representing about 96% coverage of the population. California approval was received in January 2026, while New York remains pending but has completed inspection with only minor issues already addressed.

Funding and Cost Discipline

Immunovia completed a SEK 100 million rights issue, 88% subscribed by existing shareholders, providing net proceeds of SEK 69.8 million to support launch and clinical work. Combined with earlier fundraising of more than SEK 140 million, this has funded PancreaSure’s rollout while management tightens spending.

Lower Losses and Improved Cash Burn

Financial efficiency improved meaningfully as the fourth‑quarter operating loss narrowed to SEK 16.4 million from SEK 30.1 million a year earlier, a reduction of roughly 45.5%. Quarterly cash burn was about SEK 6.6 million per month, well below prior guidance of SEK 8–10 million per month.

Operational and Commercial Team Build‑Out

To move beyond a management‑only sales effort, Immunovia hired three strategic account managers with backgrounds at Exact Sciences, Quest and Myriad. These hires are tasked with expanding outreach, integrating PancreaSure into center protocols and converting a growing pipeline of interested centers into routine users.

Structured Clinical and Reimbursement Strategy

Three clinical validation studies have been completed, two already published and the AFFIRM study pending publication, while two clinical utility studies are ongoing. A registry targeting about 400 patients in 2026 is planned to bolster real‑world evidence ahead of a mid‑2026 Medicare coverage submission with rolling data updates.

Limited Revenue Contribution So Far

Despite the scientific and commercial groundwork, current revenue remains negligible, with fourth‑quarter sales of SEK 354,000, mainly from royalties, down about 22% year on year. Management indicated that meaningful PancreaSure‑driven revenue is not expected until 2027, underscoring a prolonged build‑up period.

Coverage Still Missing Despite Pricing

While Medicare has assigned a billing code and set the USD 897 rate, the crucial step of payer coverage approval has not yet been achieved. The timing of full Medicare coverage remains uncertain and will depend heavily on the evaluation of Immunovia’s expanding clinical utility dataset.

Cash Runway and Financing Risk

The company ended December with SEK 77.5 million in cash, supported by the recent rights issue’s net proceeds. Management believes this provides runway through the third quarter of 2026 but acknowledges that additional capital will be needed to bridge to the anticipated 2027 revenue ramp.

Revenue Recognition and Collection Lag

Orders from early‑adopting centers have not yet translated into significant recognized revenue because billing to insurers only recently started. As a result, the realized average selling price per test and the pace of collections remain uncertain, adding another layer of execution risk.

Constrained Commercial Footprint to Date

Initial commercial efforts were largely carried out by the existing leadership team, limiting breadth and frequency of customer contact. The future volume ramp will depend on the effectiveness of the newly hired account managers and the outcome of ongoing negotiations for potential commercialization partnerships.

Medicare Timing and Payment Uncertainty

Management expects some reimbursement from Medicare Advantage plans and other insurers during 2026, but the scale and timing are hard to predict. Full Medicare coverage at the established USD 897 rate hinges on review timelines and prioritization, which could delay meaningful cash inflows.

Forward‑Looking Guidance and Outlook

Looking ahead, Immunovia plans to continue PancreaSure’s advocacy‑focused phase through the second quarter of 2026 while building clinical evidence, including a roughly 400‑patient registry and additional utility data. The company aims to submit for Medicare coverage in mid‑2026, expects approvals in all 50 states by then, and targets 2027 as the year when revenues should start to reflect the underlying commercial and reimbursement groundwork.

Immunovia’s earnings call painted a picture of a company with a differentiated product, solid clinical backing and disciplined financial management, yet still very much in the pre‑inflection phase of commercialization. For investors, the opportunity lies in PancreaSure’s long‑term potential, but near‑term risks around reimbursement, cash needs and the speed of adoption remain front and center.